Skip to content

e-Nose and Colorectal Cancer

Detection of Colorectal Cancer From Exhaled Air. Part II: Validation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03488537
Enrollment
511
Registered
2018-04-05
Start date
2018-02-28
Completion date
2019-12-31
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Polyps

Brief summary

Colorectal cancer (CRC) is the third most common new cancer diagnosis and a major cause of morbidity and mortality throughout the world. Early detection and treatment are critical factors in the course and prognosis of CRC, and screening programs have proven to be an important means to reduce both CRC related mortality and secondary economic burden. The diagnostic accuracy of non-invasive screening tests is still limited and a follow-up colonoscopy is required for confirmation of the diagnosis. The faecal occult blood test (FIT) is the most commonly used fecal screening test worldwide, but sensitivity for CRC ranges between 53%-99% depending on the cut-off values used, whereas sensitivity for advanced adenomas is disturbingly low (39%-57%). The aim of this study is to evaluate the diagnostic accuracy of the AeonoseTM to distuinguish people with CRC from healthy controls.

Detailed description

Rationale: An electronic nose (eNose) is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. Exhaled human breath is mainly composed of inorganic compounds, inert gases and VOCs. VOCs are exhaled in very low concentrations and reflect pathological processes such as inflammation, oxidation, infection and neoplasms. The perspective is that metabolic and biochemical processes in several pathological situations cause different endogenous VOCs to arise, were they can serve as non-invasive biomarkers for certain diseases. Primary objective: To evaluate the diagnostic accuracy of the AeonoseTM to distinguish the breathing pattern from patients with colorectal cancer from healthy controls using the previously established breathing pattern. Secondary objecitves: * To evaluate the diagnostic accuracy of the AeonoseTM to distinguish the breathing pattern from patients with polyps (e.g. advanced adenomas, sessile serrated lesions). * To determine the influence of colonic cleansing (laxative use) on breathing patterns. Study population: Adult patients referred for colonoscopy. Estimated sample size: 66 patients with CRC. Intervention: Participants will be asked to breath through the AeonoseTM for 5 minutes. There are no risks, nor benefits for the participants.

Interventions

DEVICEAeonoseTM

Breath test

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This is a Multi center prospective cohort study in subjects eligible for colonoscopy with suspicion for malignant or premalignant lesions of the colon.

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Suspicion for (pre-)malignant lesions of the colon scheduled for colonoscopy

Exclusion criteria

* Subjects with other known malignancies * Subjects with established inflammatory bowel disease

Design outcomes

Primary

MeasureTime frameDescription
sensitivity/specificity for CRC38 weeksDiagnostic accuracy of the Aeonose to detect CRC in terms of sensitivity and specificity

Secondary

MeasureTime frameDescription
sensitivity/specificity for advanced adenomas and/or sessile serrated lesions.38 weeksDiagnostic accuracy of the Aeonose to detect polyps in terms of sensitivity and specificity
Sensitivity/specificity for detection of CRC and/or polyps before and after bowel preparation38 weeksDiagnostic accuracy, sensitivity/specificity/AUC

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026